Immunohistochemical expression of sialyl lex antigen in relation to survival of patients with colorectal carcinoma

Abstract

Background. The alterations of carbohydrate chains in cancer cell membrane can be related, not only to the formation of tumor‐associated antigens, but also to cell biologic significance. There is, furthermore, a possibility of their relationship to tumor metastatic behavior and subsequent survival of patients with cancer. Recent clinical studies elucidated that a carbohydrate antigen, sialyl Lex, is a useful tumor marker in colorectal cancer. However, the sialyl Lex antigen immunoreactivity in colorectal carcinoma in relation to patient survival is unknown. The aim of the study was to elucidate whether sialyl Lex expression in tumors was correlated with patient survival. Methods. Immunohistochemical expression of sialyl Lex antigen, as detected by monoclonal antibody CSLEX1, was studied in 175 specimens of primary colorectal carcinoma from 120 patients who received radical surgery. Results. The positive expression of sialyl Lex was observed in 87 of 120 patients (72.5%). There was no statistically significant association between the negative or positive of sialyl Lex and clinicopathologic factors, excluding Dukes stage and histologic type. The difference between overall 5‐year survival of patients with sialyl Lex‐negative tumors and that of patients with sialyl Lex‐positive tumors (81.2% versus 60.6%) was statistically significant (P = 0.0263). In proportion to staining intensity that was expressed as a score based on the percentage of the total field stained positive with CSLEX1, 5‐year survival of patients indicated a worse outcome (P = 0.0113). The prognostic value was then studied in a Cox regression model. Dukes stage had the strongest association with patient survival, whereas sialyl Lex expression was found to be the second‐ranking parameter. Conclusions. When examining the expression of sialyl Lex antigen, as detected by monoclonal antibody CSLEX1, clinically useful information for patient survival after radical resection of colorectal cancer is given.

N-Acetylgalactosaminyltransferase-14 as a potential biomarker for breast cancer by immunohistochemistry

“…These alterations include aberrant glycosylation, and incomplete glycosylation. The carbohydrate antigens on the cell surface are useful for monitoring tumor status in subjects with malignant diseases [21-24]. …”

Expression of UDP- N -Acetyl-α-d-Galactosamine-Polypeptide N -Acetylgalactosaminyltransferase Isozyme 3 in the Subserosal Layer Correlates with Postsurgical Survival of Pathological Tumor Stage 2 Carcinoma of the Gallbladder

“…These alterations include aberrant glycosylation, resulting in the formation of disaccharides such as sialosyl-Tn antigen (18 -21), and incomplete glycosylation, resulting in an accumulation of mucin coreregion oligosaccharide structures such as Tn (19,(22)(23)(24)(25). These carbohydrate antigens on the cell surface are useful for monitoring tumor status in subjects with malignant diseases (19,(25)(26)(27).…”

Expression of UDP‐N‐acetyl‐α‐D‐galactosamine–polypeptide galNAc N‐acetylgalactosaminyl transferase‐3 in relation to differentiation and prognosis in patients with colorectal carcinoma

“…Recently, it has been shown that carbohydrate antigens, such as carcinoembryonic antigen, CA19-9, sialyl Tn, and Tn, are useful for monitoring tumor status in patients with malignant disease. [1][2][3] Mucin-type, O-linked carbohydrates may constitute up to 80% of the total amount of these glycoproteins. O-glycosylation has been implicated in a variety of cellular functions in tumors, such as the binding of cell-adhesion molecules, invasion, metastasis, and cell differentiation.…”